A BILL 
To amend the Federal Food, Drug, and Cosmetic Act with 
respect to limitations on exclusive approval or licensure 
of orphan drugs, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Fairness in Orphan 
4
Drug Exclusivity Act’’. 
5
SEC. 2. LIMITATIONS ON EXCLUSIVE APPROVAL OR LICEN-
6
SURE OF ORPHAN DRUGS. 
7
(a) IN GENERAL.—Section 527 of the Federal Food, 
8
Drug, and Cosmetic Act (21 U.S.C. 360cc) is amended— 
9
04:49 Oct 23, 2019
H4712
2 
•HR 4712 IH
(1) in subsection (a), by striking ‘‘Except as 
1
provided in subsection (b)’’ and inserting ‘‘Except as 
2
provided in subsection (b) or (f)’’; and 
3
(2) by adding at the end the following: 
4
‘‘(f) LIMITATIONS ON EXCLUSIVE APPROVAL, CER-
5
TIFICATION, OR LICENSE.— 
6
‘‘(1) IN
GENERAL.—For a drug designated 
7
under section 526 for a rare disease or condition 
8
pursuant to the criteria set forth in subsection 
9
(a)(2)(B) of such section, the Secretary shall not 
10
grant, recognize, or apply exclusive approval or licen-
11
sure under subsection (a), and, if such exclusive ap-
12
proval or licensure has been granted, recognized, or 
13
applied, shall revoke such exclusive approval or licen-
14
sure, unless the sponsor of the application for such 
15
drug demonstrates— 
16
‘‘(A)(i) with respect to an application ap-
17
proved or a license issued after the date of en-
18
actment of this subsection, upon such approval 
19
or issuance, that there is no reasonable expecta-
20
tion at the time of such approval or issuance 
21
that the cost of developing and making avail-
22
able in the United States such drug for such 
23
disease or condition will be recovered from sales 
24
in the United States of such drug, taking into 
25
04:49 Oct 23, 2019
H4712
3 
•HR 4712 IH
account all sales made or reasonably expected 
1
to be made without a time limitation; or 
2
‘‘(ii) with respect to an application ap-
3
proved or a license issued on or prior to the 
4
date of enactment of this subsection, not later 
5
than 60 days after such date of enactment, that 
6
there was no reasonable expectation at the time 
7
of such approval or issuance that the cost of de-
8
veloping and making available in the United 
9
States such drug for such disease or condition 
10
would be recovered from sales in the United 
11
States of such drug, taking into account all 
12
sales made or reasonably expected to be made 
13
without a time limitation; and 
14
‘‘(B) annually for the duration of the 7- 
15
year period described in subsection (a) with re-
16
spect to the drug, that there continues to be no 
17
reasonable expectation that the cost of devel-
18
oping and making available in the United 
19
States such drug for such disease or condition 
20
will be recovered from sales in the United 
21
States of such drug, taking into account all 
22
sales made or reasonably expected to be made 
23
without a time limitation. 
24
04:49 Oct 23, 2019
H4712
4 
•HR 4712 IH
‘‘(2) CONSIDERATIONS.—For purposes of sub-
1
paragraphs (A) and (B) of paragraph (1), the Sec-
2
retary and the sponsor of the application for the 
3
drug designated for a rare disease or condition de-
4
scribed in such paragraph shall consider sales from 
5
all drugs for such disease or condition that— 
6
‘‘(A) are developed or marketed by the 
7
same sponsor or manufacturer of the drug (or 
8
a licensor, predecessor in interest, or other re-
9
lated entity to the sponsor or manufacturer); 
10
and 
11
‘‘(B) contain the same active moiety as the 
12
drug, regardless of whether or not the drugs 
13
also contain different or additional active 
14
moieties. 
15
‘‘(3) CRITERIA.—No drug designated under 
16
section 526 for a rare disease or condition pursuant 
17
to the criteria set forth in subsection (a)(2)(B) of 
18
such section shall be eligible for exclusive approval 
19
or licensure under this section unless it met such 
20
criteria under such subsection on the date on which 
21
the drug was approved or licensed.’’. 
22
(b) RULE
OF CONSTRUCTION.—The amendments 
23
made in subsection (a) shall apply to any drug that has 
24
been or is hereafter designated under section 526 of the 
25
04:49 Oct 23, 2019
H4712
5 
•HR 4712 IH
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb) 
1
for a rare disease or condition pursuant to the criteria 
2
under subsection (a)(2)(B) of such section regardless of— 
3
(1) the date on which such drug is designated 
4
or becomes the subject of a designation request 
5
under such section; 
6
(2) the date on which such drug is approved 
7
under section 505 of such Act (21 U.S.C. 355) or 
8
licensed under section 351 of the Public Health 
9
Service Act (42 U.S.C. 262) or becomes the subject 
10
of an application for such approval or licensure; and 
11
(3) the date on which such drug is granted ex-
12
clusive approval or licensure under section 527 of 
13
the Federal Food, Drug, and Cosmetic Act (21 
14
U.S.C. 360cc) or becomes the subject of a request 
15
for such exclusive approval or licensure. 
16
Æ 
04:49 Oct 23, 2019
H4712
